Scrambled sirna a sc 37007

Manufactured by Santa Cruz Biotechnology

Scrambled siRNA-A (sc-37007) is a laboratory reagent used as a control in RNA interference experiments. It is a short, double-stranded RNA molecule designed to have no known mRNA target in mammalian cells.

Automatically generated - may contain errors

Lab products found in correlation

Lipofectamine rnaimax reagent, by Thermo Fisher Scientific (2 mentions) Sc 39631, by Santa Cruz Biotechnology (1 mentions) Sirna duplexes targeting, by Santa Cruz Biotechnology (1 mentions)

2 protocols using scrambled sirna a sc 37007

siRNA Knockdown of Stress Regulators

Check if the same lab product or an alternative is used in the 5 most similar protocols

The siRNA duplexes (20 to 40 nM final concentrations) targeting human NRF2 (siRNA#1: sc-37030A and siRNA#2: sc-37030B), IRE1α (sc-40705), PERK (sc-36213), KEAP1 (sc-43878) and scrambled siRNA-A (sc-37007) were from Santa Cruz Biotechnology; ATF6 siRNAs (ID22926 trilencer-27) were from Origene. Reverse transfections were performed using the Lipofectamine RNAiMAX Reagent (Invitrogen) following manufacturer’s instructions. siRNAs were incubated for 24 h prior to treatments, and protein knockdown efficiency was assessed by immunoblotting.

Zanotto-Filho A., Masamsetti V.P., Loranc E., Tonapi S.S., Gorthi A., Bernard X., Gonçalves R.M., Moreira J.C., Chen Y, & Bishop A.J. (2016). Alkylating agent induced NRF2 blocks endoplasmic reticulum stress-mediated apoptosis via control of glutathione pools and protein thiol homeostasis. Molecular cancer therapeutics, 15(12), 3000-3014.

+ Open protocol

+ Expand

siRNA Transfections for Gene Silencing

Check if the same lab product or an alternative is used in the 5 most similar protocols

Small-interference RNA (siRNA) transfections were performed using Lipofectamine RNAi MAX Reagent following manufacturer instructions (Invitrogen). siRNA duplexes targeting human IL8 (sc-39631), CXCL2 (sc-43934), MMP1 (sc-41552), VEGFA (sc-29520) PTGS2/COX-2 (sc-29279) and scrambled siRNA-A (sc-37007) were purchased from Santa Cruz Biotechnology, and incubated at 20 to 50 nM siRNA range for 24 h prior to treatments. Knockdown efficiency was confirmed by ELISA.

Zanotto-Filho A., Rajamanickam S., Loranc E., Masamsetti P., Gorthi A., Romero J.C., Tonapi S., Gonçalves R.M., Reddick R.L., Benavides R., Kuhn J., Chen Y, & Bishop A.J. (2018). Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. Cancer letters, 425, 101-115.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!